Studying high dose rate brachytherapy for localized prostate cancer in adults
Observes how high dose rate radiation implants affect prostate tumors in men with localized cancer.
Plain-language title generated from the registry record
Registry title: Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Key facts
- Where
- Kelowna, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with localized prostate cancer of favorable or low intermediate risk who will have HDR brachytherapy (internal radiation) as their only treatment.
- Age
- 18 Years or older
- Sex
- All
- Disease stage
- Localized prostate cancer, favorable risk or intermediate risk, clinical stage T1c-T2b, PSA < 20, Gleason < 8, life expectancy of at least 10 years, ECOG 0-1
- Earlier treatment
- No androgen deprivation therapy (ADT). No prior prostate surgery, pelvic radiation or chemotherapy for prostate cancer.
- Biomarker or test result
- PSA < 20 and Gleason score below 8 (for example Gleason 6 or 7 (3+4) with PSA limits given in the record)
Main reasons for not taking part
- Prior radical surgery for prostate cancer
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer
- Claustrophobia or unable to have an MRI
- Cannot have general anesthesia, cannot stop blood thinners for 24 hours, or has systemic sclerosis or inflammatory bowel disease
Read by machine on 9 November 2026.
Where in Canada
- British Columbia Cancer Center for the Southern InteriorKelowna, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT06200974
- Record updated
- 2 February 2026
- Original description
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.Read full original descriptionShow less
Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
Inclusion: Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years; Clinical stage T1c-T2b, PSA < 20, Gleason < 8; ECOG 0-1; Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA < 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml); Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA < 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density > 0.2 ng/cc,; Selected intermediate risk patients not defined above; T1c/T2a; PSA < 10 and Gleason 4+3; PSA > 10 (< 20) and Gleason 3+4; PSA 10-15 ng/ml and Gleason 4+3 and < 33% cores involved; Max tumor length in any core 10 mm; No androgen deprivation therapy (ADT); Signed study specific informed consent.
Exclusion: Prior radical surgery for carcinoma of the prostate,; Prior pelvic radiation; Prior chemotherapy for prostate cancer,; Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease; Claustrophobic or unable to undergo MRI.